Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Susan List

Psychiatry Vero Beach, FL Medical Doctor

NPI 1003323429 CMS profile 5621498

3723 10Th Ct, Vero Beach, FL 32960

Open in the dashboard

General payments

$6,101

231 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan List of Vero Beach, FL is reported in the CMS Open Payments database as having received $6,101 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,262 131
2024 General $2,839 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan List
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Susan List were reported at $3,262. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Susan List Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $2,839 $179 $57–$673 $164
2025 $3,262 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. ITI, Inc. $837 34 payments
  2. Alkermes, Inc. $780 27 payments
  3. Otsuka America Pharmaceutical, Inc. $691 23 payments
  4. Janssen Pharmaceuticals, Inc $684 21 payments
  5. Neurocrine Biosciences, Inc. $592 22 payments
  6. AbbVie, Inc. $555 27 payments
  7. Axsome Therapeutics, Inc. $407 12 payments
  8. E.R. Squibb & Sons, L.L.C. $389 14 payments
  9. Lundbeck LLC $324 18 payments
  10. Vanda Pharmaceuticals Inc. $300 10 payments
  11. Other $541 23 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $6,096 230 payments
  2. Education $5 1 payment
Products named General payments · program years 2024–2025
  1. LYBALVI $780 27 payments
  2. INGREZZA $592 22 payments
  3. REXULTI $560 15 payments
  4. CAPLYTA $549 24 payments
  5. ARISTADA Cns $537 25 payments
  6. ARISTADA Cns $537 25 payments
  7. ARISTADA Cns $537 25 payments
  8. ARISTADA Cns $537 25 payments
  9. INVEGA SUSTENNA $476 13 payments
  10. Auvelity $407 12 payments
  11. Other $3,571 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

703

Median for Psychiatry: 574

Drug cost

$56,017

Median for Psychiatry: $27,624

Branded share of claims

19.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 23 $41,727
Duloxetine Hcl Generic 40 $3,626
Bupropion Xl Bupropion Hcl Brand 55 $2,062
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 14 $1,698
Chlorpromazine Hcl Generic 11 $1,034
Mirtazapine Generic 31 $567
Gabapentin Generic 40 $561
Clonazepam Generic 50 $560
Lamotrigine Generic 32 $536
Buspirone Hcl Generic 18 $525

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $269
  • Lundbeck LLC $171
$440 23 —
VRAYLAR
  • AbbVie, Inc. $300
$300 — —
CAPLYTA
  • ITI, Inc. $288
$288 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $264
$264 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $252
$252 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record